Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
68,025.70 +957.63 (+1.43%) CMC Crypto 200
1,378.92 +48.31 (+3.63%)
Orion Oyj (ORINF)
| Previous close | 0.00 |
| Open | 47.16 |
| Bid | 42.29 x 43500 |
| Ask | 47.29 x 45100 |
| Day's range | 47.16 - 47.16 |
| 52-week range | 37.00 - 47.16 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 6.063B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 28.02 |
| EPS (TTM) | 1.37 |
| Earnings date | 08 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 15 Oct 2024 |
| 1y target est | N/A |
- GlobeNewswire
Orion publishes Half-Year Financial Report for January–June 2024 and holds a webcast on 8 August 2024
ORION CORPORATION PRESS RELEASE 25 JULY 2024 at 11.00 EEST Orion publishes Half-Year Financial Report for January–June 2024 and holds a webcast on 8 August 2024 Orion will publish Half-Year Financial Report for January–June 2024 on Thursday, 8 August 2024 at approximately 12.00 noon EEST. The report and related presentation material will be available on the company’s website at www.orion.fi/en/investors after publishing. Webcast and conference call A webcast and a conference call for analysts, i
- GlobeNewswire
Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION17 JULY 2024 at 8.30 EEST Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint Orion and Bayer’s Phase III ARANOTE trial meets primary endpoint, significantly increasing radiological progression-free survival (rPFS) with darolutamide + androgen deprivation therapy (ADT) compared to placebo plus ADT.Saf
- GlobeNewswire
Inside information: Orion upgrades full-year outlook for 2024
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION1 JULY 2024 at 15:15 EEST Inside information: Orion upgrades full-year outlook for 2024 Orion Corporation upgrades the full-year outlook for 2024 both for the part regarding net sales and operating profit. Orion and MSD (Merck & Co., Inc., Rahway, NJ, USA) have exercised the option to convert the co-development and co-commercialisation agreement with MSD regarding opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor, and
